Literature DB >> 19397589

Assessing vaccine effects in repeated low-dose challenge experiments.

Michael G Hudgens1, Peter B Gilbert.   

Abstract

Evaluation of HIV vaccine candidates in nonhuman primates (NHPs) is a critical step toward developing a successful vaccine to control the HIV pandemic. Historically, HIV vaccine regimens have been tested in NHPs by administering a single high dose of the challenge virus. More recently, evaluation of candidate HIV vaccines has entailed repeated low-dose challenges, which more closely mimic typical exposure in natural transmission settings. In this article, we consider evaluation of the type and magnitude of vaccine efficacy from such experiments. Based on the principal stratification framework, we also address evaluation of potential immunological surrogate endpoints for infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19397589      PMCID: PMC2794923          DOI: 10.1111/j.1541-0420.2009.01189.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  15 in total

Review 1.  Design and interpretation of vaccine field studies.

Authors:  M E Halloran; I M Longini; C J Struchiner
Journal:  Epidemiol Rev       Date:  1999       Impact factor: 6.222

2.  Principal stratification in causal inference.

Authors:  Constantine E Frangakis; Donald B Rubin
Journal:  Biometrics       Date:  2002-03       Impact factor: 2.571

3.  Bias reduction for risk ratio and vaccine effect estimators.

Authors:  S E Chick; D C Barth-Jones; J S Koopman
Journal:  Stat Med       Date:  2001-06-15       Impact factor: 2.373

4.  Hepatitis A and hepatitis B vaccinations: immunogenicity of combined vaccine and of simultaneously or separately applied single vaccines.

Authors:  P A Czeschinski; N Binding; U Witting
Journal:  Vaccine       Date:  2000-01-06       Impact factor: 3.641

5.  Evaluating candidate principal surrogate endpoints.

Authors:  Peter B Gilbert; Michael G Hudgens
Journal:  Biometrics       Date:  2008-03-24       Impact factor: 2.571

6.  The beta-geometric distribution applied to comparative fecundability studies.

Authors:  C R Weinberg; B C Gladen
Journal:  Biometrics       Date:  1986-09       Impact factor: 2.571

7.  Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies.

Authors:  P G Smith; L C Rodrigues; P E Fine
Journal:  Int J Epidemiol       Date:  1984-03       Impact factor: 7.196

8.  Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.

Authors:  Peter B Gilbert; Michael L Peterson; Dean Follmann; Michael G Hudgens; Donald P Francis; Marc Gurwith; William L Heyward; David V Jobes; Vladimir Popovic; Steven G Self; Faruk Sinangil; Donald Burke; Phillip W Berman
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

9.  Interpretation and estimation of vaccine efficacy under heterogeneity.

Authors:  M E Halloran; M Haber; I M Longini
Journal:  Am J Epidemiol       Date:  1992-08-01       Impact factor: 4.897

10.  Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges.

Authors:  Roland R Regoes; Ira M Longini; Mark B Feinberg; Silvija I Staprans
Journal:  PLoS Med       Date:  2005-07-19       Impact factor: 11.069

View more
  37 in total

1.  Bayesian inference for causal mediation effects using principal stratification with dichotomous mediators and outcomes.

Authors:  Michael R Elliott; Trivellore E Raghunathan; Yun Li
Journal:  Biostatistics       Date:  2010-01-25       Impact factor: 5.899

2.  Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen.

Authors:  Nicola Winstone; Aaron J Wilson; Gavin Morrow; Cesar Boggiano; Maria J Chiuchiolo; Mary Lopez; Marina Kemelman; Arielle A Ginsberg; Karl Mullen; John W Coleman; Chih-Da Wu; Sandeep Narpala; Ian Ouellette; Hansi J Dean; Feng Lin; Niranjan Y Sardesai; Holly Cassamasa; Dawn McBride; Barbara K Felber; George N Pavlakis; Alan Schultz; Michael G Hudgens; C Richter King; Timothy J Zamb; Christopher L Parks; Adrian B McDermott
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

3.  A discrete-time survival model with random effects for designing and analyzing repeated low-dose challenge experiments.

Authors:  Chaeryon Kang; Ying Huang; Christopher J Miller
Journal:  Biostatistics       Date:  2014-09-03       Impact factor: 5.899

4.  A method to address between-subject heterogeneity for identification of principal surrogate markers in repeated low-dose challenge HIV vaccine studies.

Authors:  Andrew J Spieker; Ying Huang
Journal:  Stat Med       Date:  2017-07-31       Impact factor: 2.373

5.  Analysis of repeated low-dose challenge studies.

Authors:  Tracy L Nolen; Michael G Hudgens; Pranab K Senb; Gary G Koch
Journal:  Stat Med       Date:  2015-03-09       Impact factor: 2.373

6.  Surrogates of protection in repeated low-dose challenge experiments.

Authors:  Dustin M Long; Michael G Hudgens; Chih-Da Wu
Journal:  Stat Med       Date:  2015-01-28       Impact factor: 2.373

7.  Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir.

Authors:  Charles W Dobard; Andrew Taylor; Sunita Sharma; Peter L Anderson; Lane R Bushman; Dinh Chuong; Chou-Pong Pau; Debra Hanson; Lin Wang; J Gerardo Garcia-Lerma; Ian McGowan; Lisa Rohan; Walid Heneine
Journal:  J Infect Dis       Date:  2015-06-12       Impact factor: 5.226

8.  Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.

Authors:  Huma Qureshi; Zhong-Min Ma; Ying Huang; Gregory Hodge; Michael A Thomas; Janet DiPasquale; Veronique DeSilva; Linda Fritts; Andrew J Bett; Danilo R Casimiro; John W Shiver; Marjorie Robert-Guroff; Michael N Robertson; Michael B McChesney; Peter B Gilbert; Christopher J Miller
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

Review 9.  Modeling HIV vaccine trials of the future.

Authors:  Peter B Gilbert; Ying Huang; Holly E Janes
Journal:  Curr Opin HIV AIDS       Date:  2016-11       Impact factor: 4.283

10.  Design and estimation for evaluating principal surrogate markers in vaccine trials.

Authors:  Ying Huang; Peter B Gilbert; Julian Wolfson
Journal:  Biometrics       Date:  2013-02-14       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.